CSI Market
Sign In | Register

Axim Biotechnologies Inc (AXIM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AXIM Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Axim Biotechnologies Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2024)
6 Months 		(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Operating Activities
Income-2.56
Depreciation & amortization0.00
Amortization of Other Assets0.12
Increase (Decrease) in Deferred Revenue-0.07
Severance Costs0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.02
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.04
Goodwill And Intangible Asset Impairment-
Loss From Continuing Operation-
Expenses Incurred By Related Party On Behalf Of Company-
License Fee Receivable-
Inventory Written Off-
Amortization Of Prepaid Services-
Loss On Change In Fair Value Of Derivative Liability-
Loss On Settlement Of Liability-
Increase In Escrow Receivable-
Increase In Prepaid Insurance-
Increase In Customer Deposit-
Marketable Securities Unrealized Gain Loss-
Less Gain Loss From Discontinued Operations-
Loss From Discontinued Operations Net Of Tax-
Loss From Continuing Operations-
Cost Of Goods And Services Sold Depreciation-
Noninterest Expense-
Derivative Liability Insufficient Shares-
Prepaid Insurance Expense Amortization-
Increasedecreaseinshareholder Advances-
Income taxes0.00
Marketable Securities, Unrealized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Increase (Decrease) in Receivables0.00
Accounts Payable-0.01
Increase (Decrease) in Other Accrued Liabilities0.00
Increase (Decrease) in Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.20
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.74
Discontinued operations0.00
Net Cash flow from Operating Activities-0.51
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Proceeds from Advances for Construction0.00
Cash Acquired In Acquisition-
Increase In Property And Equipment-
Acqusition Of Patents-
Increase Decrease In Property And Equipment-
Payment To Acquire Patents-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale of Loans Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.20
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.17
Issuance Of Series B And C Preferred-
Proceeds From Issuance Of Series B And C Convertible Preferred Stock-
Repayment Of Loans-
Repayment Of Loans-
Common Stock Issued Under Registration Statement On Form S-
Common Stock Issued Per Stock Purchase Agreement-
Common Stock Issued In Exchange For Debt-
Common Stock Issued In Exchange For Debt-
Stock Issued During Period Value Purchase Of Assets-
Netcashprovidedby Used In Continuingfinancingactivities-
Netcashprovidedby Used In Discontinuingfinancingactivities-
Conversion Of Stock Amount Converted0.38
Shares Issued For Severance Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.37
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.51
Total Cash Flow-0.15
4 historic quarters locked

Sign in to unlock the full Axim Biotechnologies Inc cash flow history.

Sign In Create Free Account

About Axim Biotechnologies Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240630)
  • Filed with the SEC: August 19, 2024
  • Source: axim_10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001096906-24-001772

Figures are derived from filed reports and may be restated. Historical data is subject to revision.